autologous dendritic cells loaded with autologous tumor lysate
Vaccineexperimental
Clinical trial activity
37 trials · 39 clinical orgs · 0 marketing orgs
Phase 1
26
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1992 (NCT00002505)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Diffuse Intrinsic Pontine Glioma · Phase 1
- Digestive System Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Gastrointestinal Diseases · Phase 2
- Gastrointestinal Neoplasms · Phase 2
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1
- Hamartoma · Phase 1/Phase 2
- Hodgkin Disease · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Melanoma · Phase 2
- Neoplasms · Phase 2
- Neoplasms, Nerve Tissue · Phase 1
- Neuroblastoma · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous dendritic cells incubated with irradiated autologous tumor stem cells
- autologous dendritic cells loaded with autologous tumor lysate
- autologous oxidized tumor cell lysate vaccine
- autologous tumor lysate-pulsed d-cik
- tumor cell lysate vaccine
- tumor lysate
- tumor lysate pulsed dc vaccine
- tumor lysate vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06752057 | N/A | Sep 1, 2024 | Nanchang University |
| NCT06751940 | N/A | Sep 1, 2024 | Nanchang University |
| NCT06751953 | N/A | Sep 1, 2024 | Nanchang University |
| NCT06195618 | Phase 1 | Jul 1, 2024 | Fundación Salud de los Andes, Universidad Nacional de Colombia |
| NCT06751849 | Phase 2 | Mar 11, 2024 | Nanchang University |
| NCT06545630 | Phase 1 | Nov 1, 2023 | Sichuan University |
| NCT05457959 | Phase 1 | Jan 1, 2023 | University of California, Los Angeles |
| NCT05235607 | Phase 1 | Mar 1, 2022 | Sichuan University |
| NCT05195619 | Phase 1 | Dec 10, 2021 | University of Lausanne |
| NCT05238792 | Phase 1 | Nov 17, 2021 | Georgetown University |
| NCT05023928 | Phase 1 | Sep 1, 2021 | Sichuan University |
| NCT04627246 | Phase 1 | Sep 11, 2020 | University of Lausanne |
| NCT04201873 | Phase 1 | Dec 31, 2019 | Merck, National Cancer Institute (NCI), Oncovir, Inc., Phase One Foundation, University of California, Los Angeles |
| NCT04105582 | Phase 1 | Aug 1, 2019 | Fundación Salud de los Andes, Universidad Nacional de Colombia |
| NCT03843294 | Phase 1 | Jun 30, 2019 | Georgetown University |
| NCT04147078 | Phase 1 | Jun 1, 2019 | Sichuan University |
| NCT03871205 | Phase 1 | Apr 1, 2019 | Shenzhen University |
| NCT03674073 | Phase 1 | Oct 15, 2018 | Likang Life Sciences, People's Liberation Army of China |
| NCT03652545 | Phase 1 | Sep 30, 2018 | Children's National Medical Center, Georgetown University |
| NCT03671720 | Early Phase 1 (Phase 1) | Sep 11, 2018 | Capital Medical University, Duke University |
Showing 20 of 37 trials
Page 1 / 2
Organizations
Research & Development (39)
39 organizations
Page 1 / 2